RxDoctor Payments DataLook up a doctor →

William Craig, MD

Cardiovascular Disease · Gonzales, TXNPI 1134115397

Payments from drug & device makers

$475,437in general payments, 2019–2025

Across 304 payments — averaging $1563.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$207K
  • Endotronix, Inc.$168K
  • Novartis$90K
  • Vifor (international) Ltd.$5K
  • Cvrx, Inc.$1K
  • E.r. Squibb & Sons, L.L.C.$636
  • plus $3K from 28 others

What the payments were for

  • Consulting fees$15,0006%
  • Speaking & faculty fees$8,6564%
  • Travel & lodging$9640%
  • Food & beverage$5,8202%
  • Education$590%
  • Other$206,97887%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$475,437 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$1,886,151
Medicare patients
2,093
Services billed
27,798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban915$743,682
EntrestoSacubitril/Valsartan279$238,034
XareltoRivaroxaban49$58,600
Nebivolol Hcl1,085$39,334
VascepaIcosapent Ethyl60$38,771
EdarbyclorAzilsartan Med/Chlorthalidone68$26,965
EdarbiAzilsartan Medoxomil49$23,592
BrilintaTicagrelor43$21,035
FarxigaDapagliflozin Propanediol22$16,344
Repatha SureclickEvolocumab23$15,498
Olmesartan Medoxomil808$11,872
JardianceEmpagliflozin12$9,740
LivaloPitavastatin Calcium20$8,197
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide295$8,178
Repatha SyringeEvolocumab14$8,110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$158$743,682915 claims
NovartisEntresto$90,316$238,034279 claims
Johnson & JohnsonXarelto$302$58,60049 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$205$50,557117 claims
AstraZenecaBrilinta, Farxiga$200$37,37965 claims
Boehringer IngelheimJardiance$37$9,74012 claims
Kowa Pharmaceuticals America, Inc.Livalo$82$8,19720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Gonzales

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →